{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 56,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a 2x2 grid to summarize the program's value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/26",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.4,
        "y": 0.75
      },
      "kind": "chart",
      "text": "UPCOMING CATALYSTS",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b83710f3-02f5-431a-a5cb-83e847f843e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "image",
      "text": "SPY001 antibody illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a30e23b9-1f04-4b3a-8c47-f44243191d33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.66,
        "y": 0.235
      },
      "kind": "list",
      "text": "Clinically validated pharmacology: SPY001 observed to maintain vedolizumab's epitope with similar potency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3181683b-641d-4fee-b1f4-74204f79b9cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.36,
        "y": 0.235
      },
      "kind": "list",
      "text": "Preferred target in large market: Vedolizumab is the preferred biologic in UC with >$5B in annual sales",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b3daad4-ca2f-4f3b-b39f-669ade628b0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.66,
        "y": 0.46
      },
      "kind": "list",
      "text": "Promising early data: SPY001 observed to match vedolizumab's potency and selectivity and has ~2x half-life in NHPs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bf6fbca-84a7-4b1e-9a1e-51bc56b99eb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.36,
        "y": 0.46
      },
      "kind": "list",
      "text": "Designed for differentiation: Q8W+ dosing, faster time to onset, patient-friendly formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee3a8549-d9d5-47a4-81b3-f88df00a82ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 is a potentially best-in-class anti-α4β7 mAb with near-term de-risking studies anticipated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e3758bd-5e65-4085-929f-c3224e9a6841",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "b2212ef8-30cc-4dcc-8622-3dbf86cc7012",
      "evidence": "The program summary is organized into a 2x2 grid of key value propositions.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 10,
      "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}